Neurocrine Bioscienc (NBIX)

Mar 31, 2025, 8:30 AM EDT - 3 days ago

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Mar 20, 2025, 8:30 AM EDT - 14 days ago

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Mar 17, 2025, 8:30 AM EDT - 17 days ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Mar 11, 2025, 4:01 PM EDT - 23 days ago

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Mar 5, 2025, 8:30 AM EST - 4 weeks ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Feb 27, 2025, 4:05 PM EST - 5 weeks ago

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Feb 25, 2025, 4:01 PM EST - 5 weeks ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Feb 21, 2025, 8:00 AM EST - 5 weeks ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Feb 7, 2025, 1:05 PM EST - 7 weeks ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Feb 6, 2025, 10:52 PM EST - 7 weeks ago

Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 4:01 PM EST - 2 months ago

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

Feb 4, 2025, 7:52 AM EST - 2 months ago

Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval

Jan 30, 2025, 4:01 PM EST - 2 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

Jan 28, 2025, 8:30 AM EST - 2 months ago

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Jan 27, 2025, 4:05 PM EST - 2 months ago

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Jan 23, 2025, 4:05 PM EST - 2 months ago

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Jan 21, 2025, 4:05 PM EST - 2 months ago

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Jan 13, 2025, 7:04 PM EST - 2 months ago

Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Jan 8, 2025, 8:30 AM EST - 3 months ago

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Jan 6, 2025, 4:01 PM EST - 3 months ago

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 8:00 AM EST - 3 months ago

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 18, 2024, 10:11 AM EST - 3 months ago

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Dec 13, 2024, 6:55 PM EST - 3 months ago

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 13, 2024, 5:50 PM EST - 3 months ago

US FDA approves Neurocrine Biosciences' genetic disorder drug

Nov 26, 2024, 4:01 PM EST - 4 months ago

Neurocrine Biosciences to Participate at Investor Conferences in December

Nov 8, 2024, 11:02 AM EST - 5 months ago

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

Nov 7, 2024, 8:30 AM EST - 5 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Nov 5, 2024, 4:01 PM EST - 5 months ago

Neurocrine Biosciences to Participate at Investor Conferences in November

Nov 4, 2024, 8:30 AM EST - 5 months ago

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Nov 4, 2024, 8:25 AM EST - 5 months ago

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Oct 30, 2024, 3:11 PM EDT - 5 months ago

Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 5 months ago

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Oct 10, 2024, 7:42 AM EDT - 6 months ago

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 9, 2024, 4:01 PM EDT - 6 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

Sep 30, 2024, 8:30 AM EDT - 6 months ago

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Sep 19, 2024, 4:01 PM EDT - 7 months ago

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

Sep 12, 2024, 4:31 PM EDT - 7 months ago

Neurocrine's experimental drug misses primary goal in schizophrenia trial

Sep 12, 2024, 4:05 PM EDT - 7 months ago

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Sep 10, 2024, 4:01 PM EDT - 7 months ago

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 1, 2024, 7:30 PM EDT - 7 months ago

Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Aug 29, 2024, 1:22 PM EDT - 7 months ago

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

Aug 28, 2024, 5:22 PM EDT - 7 months ago

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Aug 28, 2024, 4:05 PM EDT - 7 months ago

Neurocrine Biosciences to Participate at Investor Conferences in September

Aug 28, 2024, 1:11 PM EDT - 7 months ago

Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard

Aug 28, 2024, 11:16 AM EDT - 7 months ago

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

BMY

Aug 28, 2024, 7:07 AM EDT - 7 months ago

Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Aug 28, 2024, 7:06 AM EDT - 7 months ago

Neurocrine's schizophrenia drug meets main goal in mid-stage study

Aug 28, 2024, 7:00 AM EDT - 7 months ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia

Aug 7, 2024, 4:01 PM EDT - 8 months ago

Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

Aug 2, 2024, 10:49 AM EDT - 8 months ago

Neurocrine Biosciences Delivering Strong Core Results, And Significant Pipeline Value Could Be On The Way